Enhancing Immunotherapy Outcomes: Spatial Multi-Omics Models for Non-Small Cell Lung Cancer
David L. Rimm(Yale University), Arutha Kulasinghe(Translational Research Institute), Niki Gavrielatou(National and Kapodistrian University of Athens), Thazin Nwe Aung(Yale University), Ioannis Vathiotis(Yale Cancer Center), James Monkman(The University of Queensland), Kurt A. Schalper(Yale University), Aileen I. Fernandez(Yale University), Katherine E. Bates(C. S. Mott Children's Hospital), Jonathan Warrell(Yale University), Myrto Moutafi(University General Hospital Attikon), Chin Wee Tan(The University of Queensland), Ioannis P. Trontzas(Yale University), Ken O' Byrne(The University of Queensland), Roy S. Herbst(Smilow Cancer Hospital)
Cited by 0
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k